Additionally, Doherty exercised options to acquire 33,103 shares at $103.57 per share, as part of a Rule 10b5-1 sales plan. Following these transactions, she holds 68,412 shares directly. These moves reflect a strategic adjustment in her holdings within the company, which has maintained dividend payments for 21 consecutive years and currently offers a 1.84% yield. For deeper insights into Quest Diagnostics (NYSE:DGX)' valuation metrics and 8 additional ProTips, visit InvestingPro, where you'll find comprehensive Pro Research Reports covering what really matters about this healthcare leader.
Additionally, Doherty exercised options to acquire 33,103 shares at $103.57 per share, as part of a Rule 10b5-1 sales plan. Following these transactions, she holds 68,412 shares directly. These moves reflect a strategic adjustment in her holdings within the company, which has maintained dividend payments for 21 consecutive years and currently offers a 1.84% yield. For deeper insights into Quest Diagnostics' valuation metrics and 8 additional ProTips, visit InvestingPro, where you'll find comprehensive Pro Research Reports covering what really matters about this healthcare leader.
In other recent news, Quest Diagnostics has experienced a series of significant developments. Following robust third-quarter results, Baird slightly adjusted the stock price target for Quest Diagnostics, reducing it to $181 from $182, while maintaining an Outperform rating. The company's third-quarter revenues reached $2.49 billion, marking an 8.5% year-over-year increase, driven by organic expansion and acquisitions, including LifeLabs. Despite weather disruptions and operational challenges, Quest Diagnostics issued an optimistic full-year 2024 guidance, projecting revenues between $9.8 billion and $9.85 billion and adjusted earnings per share (EPS) of $8.85 to $8.95.
Additionally, financial services firm Leerink Partners increased their price target on Quest Diagnostics to $165 from $160, reflecting a valuation of approximately 17 times the firm's calendar year 2025 earnings per share estimate. In other company news, Quest Diagnostics is set to launch avian flu testing following contracts awarded by the U.S. Centers for Disease Control and Prevention. The company has also received a contract to develop diagnostics for the Oropouche virus, an emerging virus in the Americas. These are the recent developments surrounding Quest Diagnostics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.